Upcoming Issue Highlights

Omya Opens New Lab, Offers Enhanced R&D Services

Omya

Omya’s new pharmaceutical and nutraceutical laboratory is now operational. The facility at the company’s Swiss headquarters in Oftringen comprises a wet lab for product development, a dry lab for granulation, tableting and performance analysis, as well as storage and office space. Cutting-edge equipment—including fluid-bed technology, a roller compactor and a rotary tablet press—allows for high-quality mineral research, development and technical customer support.

Until now, Omya has done pharmaceutical and nutraceutical product development with external partners through third-party agreements. However, securing intellectual property rights in collaborations such as these can be challenging. With its own lab, Omya can react to market needs much faster now and ensures legal certainty for both itself and its customers, which is a prerequisite for the company to be able to sell its products without restrictions.

Of paramount importance for the new laboratory will be developing innovative applications and maintaining ongoing natural minerals research projects, according to the company. These include the award-winning Omyapharm, a functionalized calcium carbonate and ideal excipient that allows granules and tablets with high levels of mechanical strength and fast disintegration times to be produced. Omyapharm was selected from 20 shortlisted substances and presented with the 2015 CPhI Pharma Award for most innovative excipient.

“With the new laboratory, we are able to protect intellectual properties and further extend our specialist calcium carbonate expertise,” said Stefan Lander, vice president consumer goods at Omya. “This includes developing new structured minerals that are tailor-made for specific applications or optimizing existing products to meet the changing needs of the industry. Moreover, our experienced team of scientists and technicians is available to support customers regarding product development and ensure shorter times-to-market for pharmaceutical and nutraceutical products.”

For more information, visit www.omya.com.